EAU 2017 - Prostate Cancer - Results from #20

Viewing 21-40 of 87 articles

EAU 2017: Lessons from the ProtecT trial

EAU 2017: Con – mpMRI targeted biopsies are sufficient

EAU 2017: Con – Prostate Cancer Screening: Time to change recommendations for PSA testing

EAU 2017: Familial and genetic factors: New SNPs and panels

EAU 2017: Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling

EAU 2017: A nomogram for prediction of local cancer recurrence after primary prostate cryoablation

EAU 2017: First repeated biopsy represents the most informative predictor of progression-free survival at 3 years follow-up in patients included in an active surveillance protocol for low-risk prostate cancer

EAU 2017: A phase III study comparing partial prostate ablation versus radical prostatectomy (PART) in intermediate risk prostate cancer – initial data from the feasibility study

EAU 2017: Prospective comparative analysis of oncologic and functional outcomes between focal therapy and robotic radical prostatectomy

EAU 2017: Intra-prostatic injection of PRX302 to focally ablate clinically significant prostate cancer: An open label, phase 2a study

EAU 2017: A positive digital rectal examination (DRE) does not predict prostate cancer in 45 yr old men - results from the German risk-adapted PCA Screening Trial (PROBASE)

EAU 2017: Decipher® test impacts decision-making among patients considering adjuvant and salvage treatment following radical prostatectomy: Interim results from the multicenter prospective PRO-IMPACT study

EAU 2017: Comprehensive molecular dissection of multi-focal prostate cancer and concomitant lymph node metastasis: Implications for tissue based prognostic biomarkers

EAU 2017: Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death

EAU 2017: Targeting enzalutamide-resistant prostate cancer using the novel androgen receptor inhibitor ODM-201

EAU 2017: Systems pharmacology and quantitative proteomics for developing targeted triple therapy

EAU 2017: Is further screening of Asian men with low baseline prostate-specific antigen levels (≤ 1ng/ml) worthwhile

EAU 2017: Comparing 20,000 open prostatectomy (RRP) cases to 5,000 robotic prostatectomy (RALP) cases, he noted no differences in oncologic outcome or urinary continence

EAU 2017: Quality of life after robotic, lap, and open surgery: real different?

EAU 2017: Can pre-operative functional status (FS) or gait velocity (GV) replace cardiopulmonary exercise testing (CPET) as an independent predictor of survival and complications following radical cystectomy (RC)?

1
2
3
4
5